Biora Therapeutics Stock Performance
| BIOR Stock | USD 1.67 0.04 2.45% |
The firm shows a Beta (market volatility) of 1.67, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Biora Therapeutics will likely underperform. At this point, Biora Therapeutics has a negative expected return of -1.94%. Please make sure to confirm Biora Therapeutics' potential upside, as well as the relationship between the rate of daily change and period momentum indicator , to decide if Biora Therapeutics performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Biora Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. Even with unfluctuating performance in the last few months, the Stock's basic indicators remain relatively invariable which may send shares a bit higher in December 2024. The latest agitation may also be a sign of long-running up-swing for the enterprise retail investors. ...more
Last Split Factor 1:10 | Last Split Date 2024-10-18 |
1 | BIOR Stock Earnings Biora Therapeutics Beats EPS for Q1 2024 - MSN | 09/18/2024 |
2 | Biora Therapeutics to Present at the 19th Annual Peptide Therapeutics Symposium | 10/07/2024 |
3 | Biora Therapeutics to Reveal 00-Size BioJet Device at the 14th Annual Partnership Opportunities in Drug Delivery Meeting | 10/14/2024 |
4 | Biora Therapeutics stock falls as it looks to raise 3M via direct offering | 10/29/2024 |
5 | Biora Therapeutics to Report Third Quarter 2024 Financial Results and Provide Corporate Update | 11/07/2024 |
6 | Highbridge Capital Managements Strategic Acquisition of Biora Therapeutics Shares | 11/14/2024 |
7 | Wainwright lifts Biora Therapeutics stock target, keeps Buy rating on Q3 report | 11/18/2024 |
| Begin Period Cash Flow | 30.5 M | |
| Free Cash Flow | -48.6 M |
Biora |
Biora Therapeutics Relative Risk vs. Return Landscape
If you would invest 686.00 in Biora Therapeutics on August 26, 2024 and sell it today you would lose (519.00) from holding Biora Therapeutics or give up 75.66% of portfolio value over 90 days. Biora Therapeutics is currently does not generate positive expected returns and assumes 6.4003% risk (volatility on return distribution) over the 90 days horizon. In different words, 56% of stocks are less volatile than Biora, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Biora Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Biora Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Biora Therapeutics, and traders can use it to determine the average amount a Biora Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.3026
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | BIOR |
Estimated Market Risk
| 6.4 actual daily | 56 56% of assets are less volatile |
Expected Return
| -1.94 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.3 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Biora Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Biora Therapeutics by adding Biora Therapeutics to a well-diversified portfolio.
Biora Therapeutics Fundamentals Growth
Biora Stock prices reflect investors' perceptions of the future prospects and financial health of Biora Therapeutics, and Biora Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Biora Stock performance.
| Return On Asset | -1.25 | ||||
| Operating Margin | (49.64) % | ||||
| Current Valuation | 44 M | ||||
| Shares Outstanding | 4.52 M | ||||
| Price To Sales | 8.78 X | ||||
| Revenue | 4 K | ||||
| Gross Profit | 1.25 M | ||||
| EBITDA | (114.05 M) | ||||
| Net Income | (124.11 M) | ||||
| Cash And Equivalents | 37.06 M | ||||
| Cash Per Share | 0.19 X | ||||
| Total Debt | 47.43 M | ||||
| Current Ratio | 1.69 X | ||||
| Book Value Per Share | (36.43) X | ||||
| Cash Flow From Operations | (48.5 M) | ||||
| Earnings Per Share | 0.36 X | ||||
| Market Capitalization | 7.55 M | ||||
| Total Asset | 31.21 M | ||||
| Retained Earnings | (950.96 M) | ||||
| Working Capital | (43.9 M) | ||||
| Current Asset | 667 K | ||||
| Current Liabilities | 3.01 M | ||||
About Biora Therapeutics Performance
Assessing Biora Therapeutics' fundamental ratios provides investors with valuable insights into Biora Therapeutics' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Biora Therapeutics is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 942.76 | 989.90 | |
| Return On Tangible Assets | (4.94) | (4.69) | |
| Return On Capital Employed | 2.11 | 2.22 | |
| Return On Assets | (3.98) | (3.78) | |
| Return On Equity | 1.22 | 1.99 |
Things to note about Biora Therapeutics performance evaluation
Checking the ongoing alerts about Biora Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Biora Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Biora Therapeutics generated a negative expected return over the last 90 days | |
| Biora Therapeutics has high historical volatility and very poor performance | |
| Biora Therapeutics may become a speculative penny stock | |
| Biora Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 4 K. Net Loss for the year was (124.11 M) with profit before overhead, payroll, taxes, and interest of 1.25 M. | |
| Biora Therapeutics currently holds about 37.06 M in cash with (48.5 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.19. | |
| Biora Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Latest headline from investing.com: Wainwright lifts Biora Therapeutics stock target, keeps Buy rating on Q3 report |
- Analyzing Biora Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Biora Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Biora Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Biora Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Biora Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Biora Therapeutics' stock. These opinions can provide insight into Biora Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Biora Stock Analysis
When running Biora Therapeutics' price analysis, check to measure Biora Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biora Therapeutics is operating at the current time. Most of Biora Therapeutics' value examination focuses on studying past and present price action to predict the probability of Biora Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Biora Therapeutics' price. Additionally, you may evaluate how the addition of Biora Therapeutics to your portfolios can decrease your overall portfolio volatility.